Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

Philip A. Thompson, Alexandre Bazinet, William G. Wierda, Constantine S. Tam, Susan M. O’Brien, Satabdi Saha, Christine B. Peterson, William Plunkett, Michael J. Keating

Blood (2023) 142 (21): 1784–1788.

https://doi.org/10.1182/blood.2023020158

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 833.

https://doi.org/10.1182/blood-2023-172658

Published: 2023

Journal Articles

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 4616.

https://doi.org/10.1182/blood-2023-182256

Published: 2023

Journal Articles

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Blood (2023) 142 (Supplement 1): 3228.

https://doi.org/10.1182/blood-2023-189203

Published: 2023

Journal Articles

Myelodysplastic Syndrome Hematopoietic Stem Cells Can Undergo Differentiation Trajectory Rewiring to Escape Venetoclax Vulnerability

Juan Jose Rodriguez Sevilla, Irene Ganan-Gomez, Feiyang Ma, Kelly S. Chien, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Sanam Loghavi, Vera Adema, Natthakan Thongon, Alexandre Bazinet, Guillermo Garcia-Manero, Simona Colla

Blood (2023) 142 (Supplement 1): 584.

https://doi.org/10.1182/blood-2023-180447

Published: 2023

Journal Articles

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Alexandre Bazinet, Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short, Naval Daver, Maro Ohanian, Musa Yilmaz, Kelly S. Chien, Abhishek Maiti, Courtney D. DiNardo, Jo Ishizawa, Lucia Masarova, Debra Bull-Linderman, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 2909.

https://doi.org/10.1182/blood-2023-172883

Published: 2023

Journal Articles

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

Blood (2023) 142 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2023-172882

Published: 2023

Journal Articles

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Alex Bataller, Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4228.

https://doi.org/10.1182/blood-2023-182841

Published: 2023

Journal Articles

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Blood (2023) 142 (Supplement 1): 1857.

https://doi.org/10.1182/blood-2023-189557

Published: 2023

Journal Articles

Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial

Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2023-182250

Published: 2023

Journal Articles

CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study

Alex Bataller, Alexandre Bazinet, Gautam Borthakur, Nicholas J. Short, Elias Jabbour, Koichi Takahashi, Naval Daver, Ghayas C. Issa, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Guillermo Montalban-Bravo, William G. Wierda, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood (2023) 142 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2023-181786

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

Blood (2022) 140 (Supplement 1): 4872–4875.

https://doi.org/10.1182/blood-2022-162962

Published: 2022

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up

Blood (2022) 140 (Supplement 1): 9005–9007.

https://doi.org/10.1182/blood-2022-162918

Published: 2022

Journal Articles

A Case for Calculating 4T Scores: Predictive Value in the Diagnosis of Heparin-Induced Thrombocytopenia

Naszrin Arani, Anindita Ghosh, Alexandre Bazinet, Tapan M. Kadia, Amer Wahed

Blood (2022) 140 (Supplement 1): 11344–11345.

https://doi.org/10.1182/blood-2022-160474

Published: 2022

Journal Articles

A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Blood (2021) 138 (Supplement 1): 535.

https://doi.org/10.1182/blood-2021-153086

Published: 2021

Journal Articles

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

Blood (2021) 138 (Supplement 1): 2326.

https://doi.org/10.1182/blood-2021-150573

Published: 2021

Journal Articles

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

Samantha Worme, BSc, Selin Jessa, BSc, William Poon, BSc, Maja Jankovic, MSc, Gabriela Galicia Vazquez, PhD, Alexandre Bazinet, MD, Katharine Fooks, BSc, Isabella Iasenza, BSc, Patricia Arreba-Tutusaus, PhD, Kolja Eppert, PhD, Ioannis Ragoussis, PhD, Yu Chang Wang, PhD, Nathalie A Johnson, MD PhD, Sarit E Assouline, MD MSc, Claudia L Kleinman, PhD, François E Mercier, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143221

Published: 2020

Journal Articles

A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia

Alexandre Bazinet, MD, Ryan N Rys, BSc, BA, Claudia M Wever, PhD, Amadou Barry, Celia Greenwood, PhD, Christian Young, Alma Mendoza, Ida LaPorta, Sylvain Gimmig, François Mercier, MD, Nathalie Johnson, MD

Blood (2019) 134 (Supplement_1): 5451.

https://doi.org/10.1182/blood-2019-123904

Published: 2019

NARROW

Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up

A Phase 2 Study of the Fully Oral Combination of ASTX727 (Decitabine/Cedazuridine) Plus Venetoclax for Older and/or Unfit Patients with Acute Myeloid Leukemia

Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes

Oral Decitabine/Cedazuridine with Venetoclax in High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia: Analysis By Different Response Criteria

Myelodysplastic Syndrome Hematopoietic Stem Cells Can Undergo Differentiation Trajectory Rewiring to Escape Venetoclax Vulnerability

Decitabine/Cedazuridine (ASTX727) Combined with a Molecularly-Targeted Agent (Venetoclax, Gilteritinib, Ivosidenib, or Enasidenib) As Personalized Maintenance Therapy in Acute Myeloid Leukemia: First Results from a Phase 1b Study

Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes

Cladribine with Low Dose Cytarabine and Venetoclax Alternated with Azacytidine and Venetoclax for Acute Myeloid Leukemia: Prognostic Analysis of a Phase 2 Clinical Trial

CPX-351 with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase Ib Study

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up

A Case for Calculating 4T Scores: Predictive Value in the Diagnosis of Heparin-Induced Thrombocytopenia

A Phase I/II Study of Venetoclax in Combination with 5-Azacytidine in Treatment-Naïve and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission

Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes

A 10-Color Flow Cytometry Panel for Both Diagnosis and Minimal Residual Disease Measurement in Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only